Attached files
| file | filename |
|---|---|
| EX-3.3 - EX-3.3 - IMPEL NEUROPHARMA INC | d121817dex33.htm |
| EX-4.2 - EX-4.2 - IMPEL NEUROPHARMA INC | d121817dex42.htm |
| EX-4.3 - EX-4.3 - IMPEL NEUROPHARMA INC | d121817dex43.htm |
| EX-10.3 - EX-10.3 - IMPEL NEUROPHARMA INC | d121817dex103.htm |
| EX-10.9 - EX-10.9 - IMPEL NEUROPHARMA INC | d121817dex109.htm |
| EX-10.11 - EX-10.11 - IMPEL NEUROPHARMA INC | d121817dex1011.htm |
| EX-3.1 - EX-3.1 - IMPEL NEUROPHARMA INC | d121817dex31.htm |
| EX-21.1 - EX-21.1 - IMPEL NEUROPHARMA INC | d121817dex211.htm |
| EX-10.10 - EX-10.10 - IMPEL NEUROPHARMA INC | d121817dex1010.htm |
| S-1 - S-1 - IMPEL NEUROPHARMA INC | d121817ds1.htm |
| EX-10.2 - EX-10.2 - IMPEL NEUROPHARMA INC | d121817dex102.htm |
Exhibit 23.1
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 23, 2021, in the Registration Statement (Form S-1) and related Prospectus of Impel NeuroPharma, Inc. for the registration of shares of its common stock.
/s/ Ernst & Young LLP
April 2, 2021